Thundermist Health Center: drugs
Schedule G of this filing lists 238 drugs, with an amount and a number of claims for each, as filed. Every amount links to its page of the filing.
The schedule's total is printed as “Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for Reimbursement”. The filings describe the amounts in more than one way. Methods says more.
- 238drugs listed
- $14,485,262.62 (Schedule G, printed total, page 12 of the filing PDF)Total as filed
- 284,797 (Schedule G, printed claims total, page 12 of the filing PDF)Claims total as filed
- 27rows show “fewer than 6” for claims. What this means
All 238 drug rows
| Line | Drug | Amount as filed | Claims as filed |
|---|---|---|---|
| 1 | Biktarvy tab61958-2501-01Listed by the FDA as Biktarvybictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate50 mg; 200 mg; 25 mgtabletGilead Sciences, Inc. | 1,940,910.76 (Schedule G, line 1, page 8 of the filing PDF) | 677 |
| 2 | Ozempic inj 8 mg/3 mL00169-4772-12Listed by the FDA as Ozempicsemaglutide2.68 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 715,386.06 (Schedule G, line 2, page 8 of the filing PDF) | 2,122 |
| 3 | Ozempic inj 2 mg/3 mL00169-4181-13Listed by the FDA as Ozempicsemaglutide0.68 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 695,807.01 (Schedule G, line 3, page 8 of the filing PDF) | 1,946 |
| 4 | Ozempic inj 4 mg/3 mL00169-4130-13Listed by the FDA as Ozempicsemaglutide1.34 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 619,563.20 (Schedule G, line 4, page 8 of the filing PDF) | 1,677 |
| 5 | Cabenuva sus 600-90049702-0240-15Listed by the FDA as Cabenuvacabotegravir and rilpivirinekitViiV Healthcare Company | 418,224.87 (Schedule G, line 5, page 8 of the filing PDF) | 79 |
| 6 | Mavyret tab 100-40 mg00074-2625-28Listed by the FDA as Mavyretglecaprevir and pibrentasvir40 mg; 100 mgtablet, film coatedAbbVie Inc. | 400,487.14 (Schedule G, line 6, page 8 of the filing PDF) | 42 |
| 7 | Trelegy aer 100 mcg00173-0887-10Listed by the FDA as Trelegy Elliptafluticasone furoate, umeclidinium bromide and vilanterol trifenatate100 mcg; 62.5 mcg; 25 mcgpowderGlaxoSmithKline LLC | 276,531.85 (Schedule G, line 7, page 8 of the filing PDF) | 934 |
| 8 | Skyrizi pen inj 150 mg/mL00074-2100-01Listed by the FDA as Skyrizirisankizumab-rzaa150 mg/mLinjectionAbbVie Inc. | 246,719.65 (Schedule G, line 8, page 8 of the filing PDF) | 22 |
| 9 | Trelegy aer 200 mcg00173-0893-10Listed by the FDA as Trelegy Elliptafluticasone furoate, umeclidinium bromide and vilanterol trifenatate200 mcg; 62.5 mcg; 25 mcgpowderGlaxoSmithKline LLC | 218,123.73 (Schedule G, line 9, page 8 of the filing PDF) | 736 |
| 10 | Apretude sus 600 mg ER49702-0264-23Listed by the FDA as ApretudecabotegravirkitViiV Healthcare Company | 172,439.11 (Schedule G, line 10, page 8 of the filing PDF) | 55 |
| 11 | Sublocade inj 300 mg/1.5 mL 112496-0300-01Listed by the FDA as Sublocadebuprenorphine300 mgsolutionIndivior Inc. | 166,721.74 (Schedule G, line 11, page 8 of the filing PDF) | 125 |
| 12 | Skyrizi inj 360/2.400074-1070-01Listed by the FDA as Skyrizirisankizumab-rzaakitAbbVie Inc. | 162,609.00 (Schedule G, line 12, page 8 of the filing PDF) | 14 |
| 13 | Suboxone MIS 8-2 mg12496-1208-03Listed by the FDA as Suboxonebuprenorphine hydrochloride, naloxone hydrochloride8 mg; 2 mgfilm, solubleIndivior Inc. | 154,169.53 (Schedule G, line 13, page 8 of the filing PDF) | 438 |
| 14 | Austedo tab 12 mg68546-0172-60Listed by the FDA as Austedodeutetrabenazine12 mgtablet, coatedTeva Neuroscience, Inc. | 143,714.74 (Schedule G, line 14, page 8 of the filing PDF) | 22 |
| 15 | Wegovy inj 2.4 mg00169-4524-14Listed by the FDA as Wegovysemaglutide2.4 mg/0.75 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 141,500.68 (Schedule G, line 15, page 8 of the filing PDF) | 226 |
| 16 | Vemlidy tab 25 mg61958-2301-01Listed by the FDA as Vemlidytenofovir alafenamide25 mgtabletGilead Sciences, Inc. | 129,170.18 (Schedule G, line 16, page 8 of the filing PDF) | 135 |
| 17 | Rybelsus tab 14 mg00169-4314-30Listed by the FDA as Rybelsusoral semaglutide14 mgtabletNovo Nordisk Pharmaceutical Industries, LP | 126,120.70 (Schedule G, line 17, page 8 of the filing PDF) | 291 |
| 18 | Dovato tab 50-300 mg49702-0246-13Listed by the FDA as Dovatodolutegravir sodium and lamivudine50 mg; 300 mgtablet, film coatedViiV Healthcare Company | 124,596.71 (Schedule G, line 18, page 8 of the filing PDF) | 45 |
| 19 | Rybelsus tab 7 mg00169-4307-30Listed by the FDA as Rybelsusoral semaglutide7 mgtabletNovo Nordisk Pharmaceutical Industries, LP | 124,034.05 (Schedule G, line 19, page 8 of the filing PDF) | 306 |
| 20 | Biktarvy tab61958-2501-03Listed by the FDA as Biktarvybictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate50 mg; 200 mg; 25 mgtabletGilead Sciences, Inc. | 118,066.82 (Schedule G, line 20, page 8 of the filing PDF) | 43 |
| 21 | Vraylar cap 3 mg61874-0130-30Listed by the FDA as Vraylarcariprazine3 mgcapsule, gelatin coatedAllergan, Inc. | 117,590.46 (Schedule G, line 21, page 8 of the filing PDF) | 134 |
| 22 | Santyl OIN 250/GM50484-0010-30Listed by the FDA as Collagenase Santyl250 units/gointmentSmith & Nephew, Inc | 114,608.68 (Schedule G, line 22, page 8 of the filing PDF) | 10 |
| 23 | Nurtec tab 75 mg ODT72618-3000-02Listed by the FDA as Nurtec ODTrimegepant sulfate75 mgtablet, orally disintegratingPfizer Laboratories Div Pfizer Inc | 111,083.02 (Schedule G, line 23, page 8 of the filing PDF) | 262 |
| 24 | Vraylar cap 1.5 mg61874-0115-30Listed by the FDA as Vraylarcariprazine1.5 mgcapsule, gelatin coatedAllergan, Inc. | 107,021.91 (Schedule G, line 24, page 8 of the filing PDF) | 122 |
| 25 | Descovy tab 200/25 mg61958-2002-01Listed by the FDA as Descovyemtricitabine and tenofovir alafenamide200 mg; 25 mgtabletGilead Sciences, Inc. | 105,311.53 (Schedule G, line 25, page 8 of the filing PDF) | 95 |
| 26 | Vivitrol inj 380 mg65757-0300-01Listed by the FDA as VivitrolnaltrexonekitAlkermes, Inc. | 104,957.67 (Schedule G, line 26, page 8 of the filing PDF) | 146 |
| 27 | Sublocade inj 100 mg/0.5 mL 112496-0100-01Listed by the FDA as Sublocadebuprenorphine100 mgsolutionIndivior Inc. | 102,757.60 (Schedule G, line 27, page 8 of the filing PDF) | 76 |
| 28 | Albuterol aer HFA66993-0019-68Listed by the FDA as Albuterol Sulfate HFA90 mcgaerosol, meteredPrasco Laboratories | 102,049.95 (Schedule G, line 28, page 8 of the filing PDF) | 4,496 |
| 29 | Bupren/Nalox MIS 8-2 mg50742-0364-30Listed by the FDA as Buprenorphine and Naloxone8 mg; 2 mgfilmIngenus Pharmaceuticals, LLC | 101,992.92 (Schedule G, line 29, page 8 of the filing PDF) | 2,716 |
| 30 | Odefsey tab61958-2101-01Listed by the FDA as Odefseyemtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide200 mg; 25 mg; 25 mgtabletGilead Sciences, Inc. | 100,841.80 (Schedule G, line 30, page 8 of the filing PDF) | 45 |
| 31 | Budes/Formot aer 160-4.500310-7370-20Listed by the FDA as Budesonide and Formoterol Fumarate Dihydrate160 mcg; 4.5 mcgaerosolAstraZeneca Pharmaceuticals LP | 99,291.32 (Schedule G, line 31, page 8 of the filing PDF) | 848 |
| 32 | Caplyta cap 42 mg72060-0142-40Listed by the FDA as Caplytalumateperone42 mgcapsuleIntra-Cellular Therapies, Inc | 97,488.53 (Schedule G, line 32, page 8 of the filing PDF) | 84 |
| 33 | Wegovy inj 1.7 mg00169-4517-14Listed by the FDA as Wegovysemaglutide1.7 mg/0.75 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 96,978.71 (Schedule G, line 33, page 8 of the filing PDF) | 160 |
| 34 | Paxlovid tab 300-10000069-5321-30Listed by the FDA as Paxlovidnirmatrelvir and ritonavirkitPfizer Laboratories Div Pfizer Inc | 90,904.67 (Schedule G, line 34, page 8 of the filing PDF) | 85 |
| 35 | Wegovy inj 0.5 mg00169-4505-14Listed by the FDA as Wegovysemaglutide0.5 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 90,387.90 (Schedule G, line 35, page 8 of the filing PDF) | 157 |
| 36 | Wegovy inj 1 mg00169-4501-14Listed by the FDA as Wegovysemaglutide1 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 86,689.37 (Schedule G, line 36, page 8 of the filing PDF) | 150 |
| 37 | Rinvoq tab 15 mg ER00074-2306-30Listed by the FDA as Rinvoqupadacitinib15 mgtablet, extended releaseAbbVie Inc. | 86,406.33 (Schedule G, line 37, page 8 of the filing PDF) | 29 |
| 38 | Basaglar inj 100 units00002-7715-59Listed by the FDA as Basaglar KwikPeninsulin glargine100 IU/mLinjection, solutionEli Lilly and Company | 86,123.74 (Schedule G, line 38, page 8 of the filing PDF) | 227 |
| 39 | Mounjaro inj 5 mg/0.500002-1495-80Listed by the FDA as Mounjarotirzepatide5 mg/0.5 mLinjection, solutionEli Lilly and Company | 82,910.69 (Schedule G, line 39, page 8 of the filing PDF) | 98 |
| 40 | Wegovy inj 0.25 mg00169-4525-14Listed by the FDA as Wegovysemaglutide0.25 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 75,805.51 (Schedule G, line 40, page 8 of the filing PDF) | 132 |
| 41 | Rinvoq tab 30 mg ER00074-2310-30Listed by the FDA as Rinvoqupadacitinib30 mgtablet, extended releaseAbbVie Inc. | 75,267.12 (Schedule G, line 41, page 8 of the filing PDF) | 23 |
| 42 | Entresto tab 24-26 mg00078-0659-20Listed by the FDA as Entrestosacubitril and valsartan24 mg; 26 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 75,252.32 (Schedule G, line 42, page 9 of the filing PDF) | 229 |
| 43 | Incruse ELPT inh 62.5 mcg00173-0873-10Listed by the FDA as Incruse Elliptaumeclidinium62.5 mcgaerosol, powderGlaxoSmithKline LLC | 73,021.63 (Schedule G, line 43, page 9 of the filing PDF) | 718 |
| 44 | Vraylar cap 4.5 mg61874-0145-30Listed by the FDA as Vraylarcariprazine4.5 mgcapsule, gelatin coatedAllergan, Inc. | 70,591.50 (Schedule G, line 44, page 9 of the filing PDF) | 83 |
| 45 | Tresiba Flex inj 200 units00169-2550-13Listed by the FDA as Tresibainsulin degludec200 units/mLinjection, solutionNovo Nordisk | 69,389.01 (Schedule G, line 45, page 9 of the filing PDF) | 380 |
| 46 | Humira pen inj 40/0.4 mL00074-0554-02Listed by the FDA as HumiraadalimumabkitAbbVie Inc. | 66,182.22 (Schedule G, line 46, page 9 of the filing PDF) | 32 |
| 47 | Vraylar cap 6 mg61874-0160-30Listed by the FDA as Vraylarcariprazine6 mgcapsule, gelatin coatedAllergan, Inc. | 66,110.26 (Schedule G, line 47, page 9 of the filing PDF) | 78 |
| 48 | Qulipta tab 60 mg00074-7094-30Listed by the FDA as Quliptaatogepant60 mgtabletAbbVie Inc. | 63,652.09 (Schedule G, line 48, page 9 of the filing PDF) | 124 |
| 49 | Kisqali tab 600dose00078-0874-63Listed by the FDA as Kisqaliribociclib200 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 60,823.35 (Schedule G, line 49, page 9 of the filing PDF) | 6 |
| 50 | Tremfya inj 100 mg/mL57894-0640-11Listed by the FDA as Tremfyaguselkumab100 mg/mLinjectionJanssen Biotech, Inc. | 60,406.75 (Schedule G, line 50, page 9 of the filing PDF) | 14 |
| 51 | Dapagliflozi tab 10 mg66993-0457-30Listed by the FDA as Dapagliflozin10 mgtablet, film coatedPrasco Laboratories | 59,394.53 (Schedule G, line 51, page 9 of the filing PDF) | 219 |
| 52 | Budes/Formot aer 80-4.500310-7372-20Listed by the FDA as Budesonide and Formoterol Fumarate Dihydrate80 mcg; 4.5 mcgaerosolAstraZeneca Pharmaceuticals LP | 56,585.28 (Schedule G, line 52, page 9 of the filing PDF) | 553 |
| 53 | Cosentyx Uno inj 300/2 mL00078-1070-68Listed by the FDA as Cosentyxsecukinumab300 mg/2 mLinjectionNovartis Pharmaceuticals Corporation | 53,487.44 (Schedule G, line 53, page 9 of the filing PDF) | 19 |
| 54 | Mounjaro inj 15 mg/0.500002-1457-80Listed by the FDA as Mounjarotirzepatide15 mg/0.5 mLinjection, solutionEli Lilly and Company | 53,107.58 (Schedule G, line 54, page 9 of the filing PDF) | 61 |
| 55 | Ubrelvy tab 100 mg00023-6501-10Listed by the FDA as Ubrelvyubrogepant100 mgtabletAllergan, Inc. | 52,647.75 (Schedule G, line 55, page 9 of the filing PDF) | 100 |
| 56 | Dapagliflozi tab 5 mg66993-0456-30Listed by the FDA as Dapagliflozin5 mgtablet, film coatedPrasco Laboratories | 52,393.83 (Schedule G, line 56, page 9 of the filing PDF) | 195 |
| 57 | Zepbound inj 5/0.5 mL00002-2495-80Listed by the FDA as Zepboundtirzepatide5 mg/0.5 mLinjection, solutionEli Lilly and Company | 51,904.88 (Schedule G, line 57, page 9 of the filing PDF) | 61 |
| 58 | Mounjaro inj 7.5/0.500002-1484-80Listed by the FDA as Mounjarotirzepatide7.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 51,786.21 (Schedule G, line 58, page 9 of the filing PDF) | 64 |
| 59 | Trulicity inj 3/0.500002-2236-80Listed by the FDA as Trulicitydulaglutide3 mg/0.5 mLinjection, solutionEli Lilly and Company | 51,253.53 (Schedule G, line 59, page 9 of the filing PDF) | 63 |
| 60 | Mounjaro inj 10 mg/0.500002-1471-80Listed by the FDA as Mounjarotirzepatide10 mg/0.5 mLinjection, solutionEli Lilly and Company | 48,589.56 (Schedule G, line 60, page 9 of the filing PDF) | 54 |
| 61 | Austedo XR tab 24 mg68546-0472-56Listed by the FDA as Austedo XRdeutetrabenazine24 mgtablet, film coated, extended releaseTeva Neuroscience, Inc. | 47,305.75 (Schedule G, line 61, page 9 of the filing PDF) | 10 |
| 62 | Rexulti tab 1 mg59148-0037-13Listed by the FDA as Rexultibrexpiprazole1 mgtabletOtsuka America Pharmaceutical, Inc. | 46,474.23 (Schedule G, line 62, page 9 of the filing PDF) | 59 |
| 63 | Cosentyx pen inj 300dose00078-0639-41Listed by the FDA as Cosentyxsecukinumab150 mg/mLinjectionNovartis Pharmaceuticals Corporation | 45,131.43 (Schedule G, line 63, page 9 of the filing PDF) | 34 |
| 64 | Mounjaro inj 2.5/0.500002-1506-80Listed by the FDA as Mounjarotirzepatide2.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 45,057.90 (Schedule G, line 64, page 9 of the filing PDF) | 57 |
| 65 | Genvoya tab61958-1901-01Listed by the FDA as Genvoyaelvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide150 mg; 150 mg; 200 mg; 10 mgtabletGilead Sciences, Inc. | 44,134.79 (Schedule G, line 65, page 9 of the filing PDF) | 18 |
| 66 | Fluticas HFA aer 110 mcg66993-0079-96Listed by the FDA as Fluticasone Propionate HFA110 mcgaerosol, meteredPrasco Laboratories | 43,012.84 (Schedule G, line 66, page 9 of the filing PDF) | 429 |
| 67 | Symtuza tab59676-0800-30Listed by the FDA as Symtuzadarunavir, cobicistat, emtricitabine, and tenofovir alafenamide800 mg; 150 mg; 200 mg; 10 mgtablet, film coatedJanssen Products LP | 42,620.09 (Schedule G, line 67, page 9 of the filing PDF) | 11 |
| 68 | Santyl 250 units/g ointment 90 g50484-0010-90Listed by the FDA as Collagenase Santyl250 units/gointmentSmith & Nephew, Inc | 42,390.95 (Schedule G, line 68, page 9 of the filing PDF) | fewer than 6 (the count is not shown) |
| 69 | Bupren/Nalox MIS 8-2 mg47781-0357-03Listed by the FDA as Buprenorphine and Naloxone Sublingual Film8 mg; 2 mgfilmAlvogen Inc. | 41,770.71 (Schedule G, line 69, page 9 of the filing PDF) | 1,230 |
| 70 | Paxlovid tab 300-10000069-5045-30Listed by the FDA as Paxlovidnirmatrelvir and ritonavirkitPfizer Laboratories Div Pfizer Inc | 41,595.96 (Schedule G, line 70, page 9 of the filing PDF) | 39 |
| 71 | Testost Cyp inj 200 mg/mL00143-9659-01Listed by the FDA as Testosterone Cypionate200 mg/mLinjectionHikma Pharmaceuticals USA Inc. | 40,328.91 (Schedule G, line 71, page 9 of the filing PDF) | 1,786 |
| 72 | Juluca tab 50-25 mg49702-0242-13Listed by the FDA as Julucadolutegravir sodium and rilpivirine hydrochloride50 mg; 25 mgtablet, film coatedViiV Healthcare Company | 40,014.92 (Schedule G, line 72, page 9 of the filing PDF) | 16 |
| 73 | Tiotrop Brom cap 18 mcg68180-0964-12Listed by the FDA as Tiotropium Bromide18 mcgcapsuleLupin Pharmaceuticals, Inc. | 37,459.50 (Schedule G, line 73, page 9 of the filing PDF) | 184 |
| 74 | Skyrizi sol 60 mg/mL00074-5015-01Listed by the FDA as Skyrizirisankizumab-rzaa600 mg/10 mLinjectionAbbVie Inc. | 37,153.93 (Schedule G, line 74, page 9 of the filing PDF) | fewer than 6 (the count is not shown) |
| 75 | Zepbound inj 2.5/0.500002-2506-80Listed by the FDA as Zepboundtirzepatide2.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 36,958.68 (Schedule G, line 75, page 9 of the filing PDF) | 45 |
| 76 | Tivicay tab 50 mg49702-0228-13Listed by the FDA as Tivicaydolutegravir sodium50 mgtablet, film coatedViiV Healthcare Company | 35,603.69 (Schedule G, line 76, page 9 of the filing PDF) | 13 |
| 77 | Austedo tab 9 mg68546-0171-60Listed by the FDA as Austedodeutetrabenazine9 mgtablet, coatedTeva Neuroscience, Inc. | 35,241.92 (Schedule G, line 77, page 9 of the filing PDF) | 6 |
| 78 | Zepbound inj 7.5/0.500002-2484-80Listed by the FDA as Zepboundtirzepatide7.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 34,605.79 (Schedule G, line 78, page 9 of the filing PDF) | 38 |
| 79 | Epinephrine inj 0.3 mg00115-1694-49Listed by the FDA as Epinephrine0.3 mg/0.3 mLinjectionAmneal Pharmaceuticals of New York LLC | 33,982.09 (Schedule G, line 79, page 9 of the filing PDF) | 363 |
| 80 | Combivent aer 20-10000597-0024-02Listed by the FDA as Combivent Respimatipratropium bromide and albuterol20 mcg; 100 mcgspray, meteredBoehringer Ingelheim Pharmaceuticals, Inc. | 33,043.06 (Schedule G, line 80, page 9 of the filing PDF) | 138 |
| 81 | Adbry inj 300/2 mL50222-0350-02Listed by the FDA as Adbrytralokinumab-ldrm300 mg/2 mLinjection, solutionLEO Pharma Inc. | 32,939.90 (Schedule G, line 81, page 9 of the filing PDF) | 13 |
| 82 | Caplyta cap 21 mg72060-0121-40Listed by the FDA as Caplytalumateperone21 mgcapsuleIntra-Cellular Therapies, Inc | 32,362.13 (Schedule G, line 82, page 9 of the filing PDF) | 31 |
| 83 | Skyrizi inj 150 mg/mL00074-1050-01Listed by the FDA as Skyrizirisankizumab-rzaa150 mg/mLinjectionAbbVie Inc. | 32,201.66 (Schedule G, line 83, page 9 of the filing PDF) | fewer than 6 (the count is not shown) |
| 84 | Zubsolv SUB 8.6-2.154123-0986-30Listed by the FDA as Zubsolvbuprenorphine hydrochloride and naloxone hydrochloride8.6 mg; 2.1 mgtablet, orally disintegratingOrexo US, Inc. | 32,022.63 (Schedule G, line 84, page 9 of the filing PDF) | 56 |
| 85 | Trulicity inj 4.5/0.500002-3182-80Listed by the FDA as Trulicitydulaglutide4.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 31,875.97 (Schedule G, line 85, page 9 of the filing PDF) | 29 |
| 86 | Lantus Solos inj 100/mL00088-2219-05Listed by the FDA as Lantus Solostarinsulin glargine100 IU/mLinjection, solutionsanofi-aventis U.S. LLC | 29,139.66 (Schedule G, line 86, page 9 of the filing PDF) | 1,236 |
| 87 | Xifaxan tab 550 mg65649-0303-02Listed by the FDA as Xifaxanrifaximin550 mgtabletSalix Pharmaceuticals, Inc. | 29,041.25 (Schedule G, line 87, page 9 of the filing PDF) | 40 |
| 88 | Zepbound inj 10/0.5 mL00002-2471-80Listed by the FDA as Zepboundtirzepatide10 mg/0.5 mLinjection, solutionEli Lilly and Company | 28,786.52 (Schedule G, line 88, page 9 of the filing PDF) | 35 |
| 89 | Austedo XR tab 12 mg68546-0471-56Listed by the FDA as Austedo XRdeutetrabenazine12 mgtablet, film coated, extended releaseTeva Neuroscience, Inc. | 28,523.01 (Schedule G, line 89, page 9 of the filing PDF) | 9 |
| 90 | Mounjaro inj 12.5/0.500002-1460-80Listed by the FDA as Mounjarotirzepatide12.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 28,510.89 (Schedule G, line 90, page 9 of the filing PDF) | 37 |
| 91 | Stelara inj 90 mg/mL57894-0061-03Listed by the FDA as Stelaraustekinumab90 mg/mLinjection, solutionJanssen Biotech, Inc. | 28,125.92 (Schedule G, line 91, page 9 of the filing PDF) | fewer than 6 (the count is not shown) |
| 92 | Fluticas HFA aer 44 mcg66993-0078-96Listed by the FDA as Fluticasone Propionate HFA44 mcgaerosol, meteredPrasco Laboratories | 27,655.07 (Schedule G, line 92, page 9 of the filing PDF) | 345 |
| 93 | Umeclid/VILA inh 62.5-2566993-0134-97Listed by the FDA as Umeclidinium and Vilanterol Elliptaumeclidinium bromide and vilanterol trifenatate62.5 mcg; 25 mcgpowderPrasco Laboratories | 27,492.29 (Schedule G, line 93, page 9 of the filing PDF) | 108 |
| 94 | Rexulti tab 2 mg59148-0038-13Listed by the FDA as Rexultibrexpiprazole2 mgtabletOtsuka America Pharmaceutical, Inc. | 27,299.15 (Schedule G, line 94, page 9 of the filing PDF) | 31 |
| 95 | Delstrigo tab00006-5007-01Listed by the FDA as Delstrigodoravirine, lamivudine, and tenofovir disoproxil fumarate100 mg; 300 mg; 300 mgtablet, film coatedMerck Sharp & Dohme LLC | 27,283.94 (Schedule G, line 95, page 9 of the filing PDF) | 14 |
| 96 | Entresto tab 49-51 mg00078-0777-20Listed by the FDA as Entrestosacubitril and valsartan49 mg; 51 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 27,207.91 (Schedule G, line 96, page 9 of the filing PDF) | 57 |
| 97 | Wixela Inhub aer 250/5000378-9321-32Listed by the FDA as Wixela Inhubfluticasone propionate and salmeterol250 mcg; 50 mcgpowderMylan Pharmaceuticals Inc. | 26,329.82 (Schedule G, line 97, page 9 of the filing PDF) | 554 |
| 98 | Abilify ASIM inj 960 mg59148-0114-80Listed by the FDA as Abilify Asimtufiiaripiprazole960 mg/3.2 mLinjection, suspension, extended releaseOtsuka America Pharmaceutical, Inc | 25,993.23 (Schedule G, line 98, page 9 of the filing PDF) | 6 |
| 99 | Rexulti tab 3 mg59148-0039-13Listed by the FDA as Rexultibrexpiprazole3 mgtabletOtsuka America Pharmaceutical, Inc. | 25,265.51 (Schedule G, line 99, page 9 of the filing PDF) | 32 |
| 100 | Rybelsus tab 3 mg00169-4303-30Listed by the FDA as Rybelsusoral semaglutide3 mgtabletNovo Nordisk Pharmaceutical Industries, LP | 25,204.86 (Schedule G, line 100, page 9 of the filing PDF) | 70 |
| 101 | Epclusa tab 400-10061958-2201-01Listed by the FDA as Epclusavelpatasvir and sofosbuvir100 mg; 400 mgtablet, film coatedGilead Sciences, Inc. | 24,593.92 (Schedule G, line 101, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 102 | Wixela Inhub aer 500/5000378-9322-32Listed by the FDA as Wixela Inhubfluticasone propionate and salmeterol500 mcg; 50 mcgpowderMylan Pharmaceuticals Inc. | 23,652.93 (Schedule G, line 102, page 10 of the filing PDF) | 247 |
| 103 | Dovato tab 50-300 mg49702-0246-33Listed by the FDA as Dovatodolutegravir sodium and lamivudine50 mg; 300 mgtablet, film coatedViiV Healthcare Company | 23,152.83 (Schedule G, line 103, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 104 | Zenpep cap 40,000 units73562-0114-01Listed by the FDA as Zenpeppancrelipase lipase, pancrelipase protease, pancrelipase amylase40,000 USP units; 126,000 USP units; 168,000 USP unitscapsule, delayed releaseAimmune Therapeutics, Inc. | 22,583.41 (Schedule G, line 104, page 10 of the filing PDF) | 9 |
| 105 | Kisqali FCT tab 200 mg00078-0860-01Listed by the FDA as Kisqaliribociclib200 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 22,362.16 (Schedule G, line 105, page 10 of the filing PDF) | 6 |
| 106 | Radicava ORS sus 105/5 mL70510-2322-01Listed by the FDA as Radicava ORSedaravonekitShionogi Inc. | 21,885.60 (Schedule G, line 106, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 107 | Verzenio tab 150 mg00002-5337-54Listed by the FDA as Verzenioabemaciclib150 mgtabletEli Lilly and Company | 21,737.12 (Schedule G, line 107, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 108 | Zepbound inj 12.5/0.500002-2460-80Listed by the FDA as Zepboundtirzepatide12.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 21,291.08 (Schedule G, line 108, page 10 of the filing PDF) | 24 |
| 109 | Fluticas HFA aer 220 mcg66993-0080-96Listed by the FDA as Fluticasone Propionate HFA220 mcgaerosol, meteredPrasco Laboratories | 20,805.36 (Schedule G, line 109, page 10 of the filing PDF) | 123 |
| 110 | Invega SUST inj 234/1.550458-0564-01Listed by the FDA as Invega Sustennapaliperidone palmitate234 mg/1.5 mLinjectionJanssen Pharmaceuticals, Inc. | 19,773.25 (Schedule G, line 110, page 10 of the filing PDF) | 15 |
| 111 | Stiolto aer 2.5-2.500597-0155-61Listed by the FDA as Stiolto Respimattiotropium bromide and olodaterol3.124 mcg; 2.736 mcgspray, meteredBoehringer Ingelheim Pharmaceuticals, Inc. | 19,687.43 (Schedule G, line 111, page 10 of the filing PDF) | 192 |
| 112 | Breo Ellipta inh 100-2500173-0859-10Listed by the FDA as Breo Elliptafluticasone furoate and vilanterol trifenatate100 mcg; 25 mcgpowderGlaxoSmithKline LLC | 19,562.31 (Schedule G, line 112, page 10 of the filing PDF) | 178 |
| 113 | Trulicity inj 0.75/0.500002-1433-80Listed by the FDA as Trulicitydulaglutide0.75 mg/0.5 mLinjection, solutionEli Lilly and Company | 19,427.79 (Schedule G, line 113, page 10 of the filing PDF) | 43 |
| 114 | Norelge/ETHI DIS 150/3570710-1190-03Listed by the FDA as Norelgestromin and Ethinyl Estradiol150 mcg/mg; 35 mcg/mgpatchZydus Pharmaceuticals USA Inc. | 19,063.19 (Schedule G, line 114, page 10 of the filing PDF) | 294 |
| 115 | Tremfya SY 200 mg/mL 2 mL PF PPN57894-0651-02Listed by the FDA as Tremfyaguselkumab200 mg/2 mLinjectionJanssen Biotech, Inc. | 19,013.76 (Schedule G, line 115, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 116 | Rexulti tab 4 mg59148-0040-13Listed by the FDA as Rexultibrexpiprazole4 mgtabletOtsuka America Pharmaceutical, Inc. | 18,362.48 (Schedule G, line 116, page 10 of the filing PDF) | 21 |
| 117 | Bupren/Nalox SUB 8-2 mg00054-0189-13Listed by the FDA as Buprenorphine and Naloxone8 mg; 2 mgtabletHikma Pharmaceuticals USA Inc. | 18,152.68 (Schedule G, line 117, page 10 of the filing PDF) | 732 |
| 118 | Qvar Rediha aer 80 mcg59310-0304-80Listed by the FDA as Qvar Redihalerbeclomethasone dipropionate HFA80 mcgaerosol, meteredTeva Respiratory, LLC | 17,508.44 (Schedule G, line 118, page 10 of the filing PDF) | 190 |
| 119 | Albuterol aer HFA69097-0142-60Listed by the FDA as Albuterol Sulfate90 mcginhalantCipla USA Inc. | 17,284.36 (Schedule G, line 119, page 10 of the filing PDF) | 3,784 |
| 120 | Breztri aero aer Sphere00310-4616-12Listed by the FDA as Breztribudesonide, glycopyrrolate, and formoterol fumarate160 mcg; 9 mcg; 4.8 mcgaerosol, meteredAstraZeneca Pharmaceuticals LP | 17,269.87 (Schedule G, line 120, page 10 of the filing PDF) | 65 |
| 121 | Tresiba Flex inj 100 units00169-2660-15Listed by the FDA as Tresibainsulin degludec100 units/mLinjection, solutionNovo Nordisk | 17,062.31 (Schedule G, line 121, page 10 of the filing PDF) | 147 |
| 122 | Prezcobix tab 800-15059676-0575-30Listed by the FDA as Prezcobixdarunavir ethanolate and cobicistat800 mg; 150 mgtablet, film coatedJanssen Products, LP | 16,849.20 (Schedule G, line 122, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 123 | Breo Ellipta inh 200-2500173-0882-10Listed by the FDA as Breo Elliptafluticasone furoate and vilanterol trifenatate200 mcg; 25 mcgpowderGlaxoSmithKline LLC | 16,664.14 (Schedule G, line 123, page 10 of the filing PDF) | 148 |
| 124 | Trulicity inj 1.5/0.500002-1434-80Listed by the FDA as Trulicitydulaglutide1.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 16,448.21 (Schedule G, line 124, page 10 of the filing PDF) | 38 |
| 125 | Triumeq tab (ABC600/DTG50/3TC 300)49702-0231-13Listed by the FDA as Triumeqabacavir sulfate, dolutegravir sodium, lamivudine600 mg; 50 mg; 300 mgtablet, film coatedViiV Healthcare Company | 16,392.41 (Schedule G, line 125, page 10 of the filing PDF) | 8 |
| 126 | Fluticasone spr 50 mcg00054-3270-99Listed by the FDA as Fluticasone Propionate50 mcgspray, meteredHikma Pharmaceuticals USA Inc. | 16,049.07 (Schedule G, line 126, page 10 of the filing PDF) | 4,528 |
| 127 | Anoro Ellipt aer 62.5-2500173-0869-10Listed by the FDA as Anoro Elliptaumeclidinium bromide and vilanterol trifenatate62.5 mcg; 25 mcgpowderGlaxoSmithKline LLC | 16,035.90 (Schedule G, line 127, page 10 of the filing PDF) | 249 |
| 128 | Albuterol aer HFA00093-3174-31Listed by the FDA as Albuterol Sulfate HFA90 mcgaerosol, meteredTeva Pharmaceuticals USA, Inc. | 15,771.88 (Schedule G, line 128, page 10 of the filing PDF) | 2,085 |
| 129 | Spiriva RESP aer 1.25 mcg00597-0160-61Listed by the FDA as Spiriva Respimattiotropium bromide inhalation spray1.562 mcgspray, meteredBoehringer Ingelheim Pharmaceuticals, Inc. | 15,729.13 (Schedule G, line 129, page 10 of the filing PDF) | 233 |
| 130 | Actemra inj 162/0.950242-0138-01Listed by the FDA as Actemratocilizumab162 mg/0.9 mLinjection, solutionGenentech, Inc. | 15,617.80 (Schedule G, line 130, page 10 of the filing PDF) | 7 |
| 131 | Gvoke Hypo 2 inj 1/0.2 mL72065-0121-12Listed by the FDA as Gvoke HypoPen 1 mg Auto-Injectorglucagon injection, solution1 mg/0.2 mLinjection, solutionXeris Pharmaceuticals, Inc. | 15,508.12 (Schedule G, line 131, page 10 of the filing PDF) | 31 |
| 132 | Zubsolv SUB 5.7-1.454123-0957-30Listed by the FDA as Zubsolvbuprenorphine hydrochloride and naloxone hydrochloride5.7 mg; 1.4 mgtablet, orally disintegratingOrexo US, Inc. | 15,448.97 (Schedule G, line 132, page 10 of the filing PDF) | 56 |
| 133 | Botox 200 units inj, 1 vial00023-3921-02Listed by the FDA as BotoxonabotulinumtoxinA200 USP unitsinjection, powder, lyophilized, for solutionAllergan, Inc. | 15,413.51 (Schedule G, line 133, page 10 of the filing PDF) | 18 |
| 134 | Toujeo Max inj 300/mL00024-5871-02Listed by the FDA as Toujeo Maxinsulin glargine300 units/mLinjection, solutionSanofi-Aventis U.S. LLC | 15,237.53 (Schedule G, line 134, page 10 of the filing PDF) | 103 |
| 135 | Estrad Val inj 20 mg/mL70700-0274-22Listed by the FDA as Estradiol valerate20 mg/mLinjectionXiromed, LLC | 15,209.62 (Schedule G, line 135, page 10 of the filing PDF) | 213 |
| 136 | Entresto tab 97-103 mg00078-0696-20Listed by the FDA as Entrestosacubitril and valsartan97 mg; 103 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 14,858.97 (Schedule G, line 136, page 10 of the filing PDF) | 44 |
| 137 | Xyosted inj 75/0.5 mL54436-0275-04Listed by the FDA as Xyostedtestosterone enanthate75 mg/0.5 mLinjectionAntares Pharma, Inc. | 14,701.89 (Schedule G, line 137, page 10 of the filing PDF) | 46 |
| 138 | Gemtesa tab 75 mg73336-0075-30Listed by the FDA as Gemtesavibegron75 mgtablet, film coatedSumitomo Pharma America, Inc. | 14,418.44 (Schedule G, line 138, page 10 of the filing PDF) | 61 |
| 139 | Arnuity ELPT inh 200 mcg00173-0876-10Listed by the FDA as Arnuity Elliptafluticasone furoate200 mcgpowderGlaxoSmithKline LLC | 14,399.94 (Schedule G, line 139, page 10 of the filing PDF) | 196 |
| 140 | Naltrexone tab 50 mg47335-0326-88Listed by the FDA as Naltrexone Hydrochloride50 mgtablet, film coatedSun Pharmaceutical Industries, Inc. | 14,017.99 (Schedule G, line 140, page 10 of the filing PDF) | 776 |
| 141 | Zepbound inj 15/0.5 mL00002-2457-80Listed by the FDA as Zepboundtirzepatide15 mg/0.5 mLinjection, solutionEli Lilly and Company | 13,979.05 (Schedule G, line 141, page 10 of the filing PDF) | 17 |
| 142 | Viberzi tab 100 mg61874-0100-60Listed by the FDA as Viberzieluxadoline100 mgtablet, film coatedAllergan, Inc. | 13,880.85 (Schedule G, line 142, page 10 of the filing PDF) | 21 |
| 143 | Epinephrine inj 0.3 mg00093-5986-27Listed by the FDA as Epinephrine0.3 mg/0.3 mLinjectionTeva Pharmaceuticals USA, Inc. | 13,850.85 (Schedule G, line 143, page 10 of the filing PDF) | 65 |
| 144 | Toujeo Solo inj 300/mL00024-5869-03Listed by the FDA as Toujeoinsulin glargine300 units/mLinjection, solutionSanofi-Aventis U.S. LLC | 13,464.71 (Schedule G, line 144, page 10 of the filing PDF) | 132 |
| 145 | Auvelity tab 45-105 mg81968-0045-60Listed by the FDA as Auvelitydextromethorphan hydrobromide, bupropion hydrochloride45 mg; 105 mgtablet, multilayer, extended releaseAxsome Therapeutics, Inc. | 13,458.60 (Schedule G, line 145, page 10 of the filing PDF) | 23 |
| 146 | Lidocaine pad 4%70512-0014-30Listed by the FDA as Lidocaine 4% Patchlidocaine 4%40 mg/gpatchSOLA Pharmaceuticals | 12,904.10 (Schedule G, line 146, page 10 of the filing PDF) | 60 |
| 147 | Liraglutide inj 18 mg/3 mL00480-7250-46Listed by the FDA as Liraglutide6 mg/mLinjection, solutionTeva Pharmaceuticals, Inc. | 12,765.24 (Schedule G, line 147, page 10 of the filing PDF) | 13 |
| 148 | Rexulti tab 0.5 mg59148-0036-13Listed by the FDA as Rexultibrexpiprazole0.5 mgtabletOtsuka America Pharmaceutical, Inc. | 12,705.84 (Schedule G, line 148, page 10 of the filing PDF) | 16 |
| 149 | Lidocaine DIS 5% patch00603-1880-16Listed by the FDA as Lidocaine50 mg/gpatchPar Health USA, LLC | 12,456.93 (Schedule G, line 149, page 10 of the filing PDF) | 516 |
| 150 | Qvar Redihal aer 40 mcg59310-0302-40Listed by the FDA as Qvar Redihalerbeclomethasone dipropionate HFA40 mcgaerosol, meteredTeva Respiratory, LLC | 12,441.99 (Schedule G, line 150, page 10 of the filing PDF) | 197 |
| 151 | Ibuprofen tab 800 mg49483-0604-50Listed by the FDA as Ibuprofen800 mgtablet, film coatedTime Cap Laboratories, Inc | 11,900.73 (Schedule G, line 151, page 10 of the filing PDF) | 3,007 |
| 152 | Oseltamivir cap 75 mg60219-1266-01Listed by the FDA as Oseltamivir Phosphateoseltamivir75 mgcapsuleAmneal Pharmaceuticals LLC | 11,827.11 (Schedule G, line 152, page 10 of the filing PDF) | 559 |
| 153 | Glargin yfgn inj 100 units/mL83257-0015-32Listed by the FDA as Insulin Glargineinsulin glargine-yfgn100 IU/mLinjection, solutionBiocon Biologics Inc. | 11,821.16 (Schedule G, line 153, page 10 of the filing PDF) | 147 |
| 154 | Abilify Asmtfl PFS720 mg2.4 mL 159148-0102-80Listed by the FDA as Abilify Asimtufiiaripiprazole720 mg/2.4 mLinjection, suspension, extended releaseOtsuka America Pharmaceutical, Inc | 11,782.25 (Schedule G, line 154, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 155 | Nicotine TD DIS 21 mg/24H00536-5896-88Listed by the FDA as Nicotine21 mg/24 hourspatchRugby Laboratories | 11,518.32 (Schedule G, line 155, page 10 of the filing PDF) | 491 |
| 156 | Ubrelvy tab 50 mg00023-6498-10Listed by the FDA as Ubrelvyubrogepant50 mgtabletAllergan, Inc. | 11,360.36 (Schedule G, line 156, page 10 of the filing PDF) | 32 |
| 157 | Emverm CHW 100 mg64896-0669-30 | 11,199.60 (Schedule G, line 157, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 158 | Wixela Inhub aer 100/5000378-9320-32Listed by the FDA as Wixela Inhubfluticasone propionate and salmeterol100 mcg; 50 mcgpowderMylan Pharmaceuticals Inc. | 11,160.68 (Schedule G, line 158, page 10 of the filing PDF) | 289 |
| 159 | Xcopri tab 200 mg71699-0200-30Listed by the FDA as Xcopricenobamate200 mgtablet, film coatedSK Life Science, Inc. | 11,118.81 (Schedule G, line 159, page 10 of the filing PDF) | 15 |
| 160 | Ajovy inj 225/1.551759-0202-10Listed by the FDA as Ajovyfremanezumab-vfrm225 mg/1.5 mLinjectionTeva Pharmaceuticals USA, Inc. | 11,005.32 (Schedule G, line 160, page 11 of the filing PDF) | 57 |
| 161 | Alogliptin tab 25 mg45802-0150-65Listed by the FDA as Alogliptin25 mgtablet, film coatedPadagis Israel Pharmaceuticals Ltd | 10,855.85 (Schedule G, line 161, page 11 of the filing PDF) | 108 |
| 162 | Steglatro tab 15 mg00006-5364-03Listed by the FDA as Steglatroertugliflozin15 mgtablet, film coatedMerck Sharp & Dohme LLC | 10,317.22 (Schedule G, line 162, page 11 of the filing PDF) | 36 |
| 163 | Humira inj 40/0.4 mL00074-0243-02Listed by the FDA as HumiraadalimumabkitAbbVie Inc. | 9,931.73 (Schedule G, line 163, page 11 of the filing PDF) | 7 |
| 164 | Novolog inj Flexpen00169-6339-10Listed by the FDA as Novologinsulin aspart100 IU/mLinjection, solutionNovo Nordisk | 9,846.54 (Schedule G, line 164, page 11 of the filing PDF) | 81 |
| 165 | Nubeqa tab 300 mg50419-0395-01Listed by the FDA as Nubeqadarolutamide300 mgtablet, film coatedBayer HealthCare Pharmaceuticals Inc. | 9,590.52 (Schedule G, line 165, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 166 | Valtoco spr 10 mg72252-0510-05Listed by the FDA as Valtocodiazepam10 mg/0.1 mLsprayNeurelis, Inc | 9,497.48 (Schedule G, line 166, page 11 of the filing PDF) | 8 |
| 167 | Saxenda inj 18 mg/3 mL00169-2800-15Listed by the FDA as Saxendaliraglutide6 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 9,403.18 (Schedule G, line 167, page 11 of the filing PDF) | 21 |
| 168 | Trintellix tab 20 mg64764-0750-30Listed by the FDA as Trintellixvortioxetine20 mgtablet, film coatedTakeda Pharmaceuticals America, Inc. | 9,399.11 (Schedule G, line 168, page 11 of the filing PDF) | 124 |
| 169 | Arnuity ELPT inh 100 mcg00173-0874-10Listed by the FDA as Arnuity Elliptafluticasone furoate100 mcgpowderGlaxoSmithKline LLC | 9,345.16 (Schedule G, line 169, page 11 of the filing PDF) | 188 |
| 170 | Epinephrine inj 0.15 mg00093-5985-27Listed by the FDA as Epinephrine0.15 mg/0.3 mLinjectionTeva Pharmaceuticals USA, Inc. | 9,148.82 (Schedule G, line 170, page 11 of the filing PDF) | 41 |
| 171 | Estrad Val inj 10 mg/mL70700-0273-22Listed by the FDA as Estradiol valerate10 mg/mLinjectionXiromed, LLC | 8,840.57 (Schedule G, line 171, page 11 of the filing PDF) | 91 |
| 172 | Prolia inj 60 mg/mL55513-0710-21Listed by the FDA as Proliadenosumab60 mg/mLinjectionAmgen, Inc | 8,321.73 (Schedule G, line 172, page 11 of the filing PDF) | 10 |
| 173 | Nicotine TD DIS 14 mg/24H00536-5895-88Listed by the FDA as Nicotine14 mg/24 hourspatchRugby Laboratories | 8,279.59 (Schedule G, line 173, page 11 of the filing PDF) | 339 |
| 174 | Flutic/Vilan inh 100-2566993-0135-97Listed by the FDA as Fluticasone Furoate and Vilanterol100 mcg; 25 mcgpowderPrasco Laboratories | 8,201.81 (Schedule G, line 174, page 11 of the filing PDF) | 55 |
| 175 | Slynd tab 4 mg00642-7470-01Listed by the FDA as SlynddrospirenonekitExeltis USA, Inc. | 8,094.44 (Schedule G, line 175, page 11 of the filing PDF) | 38 |
| 176 | Hydrocort AC SUP 25 mg00574-7090-12Listed by the FDA as Hydrocortisone Acetate25 mgsuppositoryPadagis US LLC | 8,081.76 (Schedule G, line 176, page 11 of the filing PDF) | 33 |
| 177 | Tremfya PFS 100 mg/mL 157894-0640-01Listed by the FDA as Tremfyaguselkumab100 mg/mLinjectionJanssen Biotech, Inc. | 7,971.76 (Schedule G, line 177, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 178 | Nicotine POL gum 4 mg00536-3405-01Listed by the FDA as Nicotinenicotine polacrilex4 mggum, chewingRugby Laboratories | 7,959.55 (Schedule G, line 178, page 11 of the filing PDF) | 229 |
| 179 | Fasenra pen inj 30 mg/mL00310-1830-30Listed by the FDA as Fasenrabenralizumab30 mg/mLinjection, solutionAstraZeneca Pharmaceuticals LP | 7,860.75 (Schedule G, line 179, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 180 | Contrave tab 8-90 mg51267-0890-99Listed by the FDA as Contrave Extended-Releasenaltrexone hydrochloride and bupropion hydrochloride8 mg; 90 mgtablet, extended releaseNalpropion Pharmaceuticals LLC | 7,854.35 (Schedule G, line 180, page 11 of the filing PDF) | 13 |
| 181 | Xolair inj 300/2 mL50242-0227-55Listed by the FDA as Xolairomalizumab300 mg/2 mLinjection, solutionGenentech, Inc. | 7,769.78 (Schedule G, line 181, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 182 | Mirabegron tab 50 mg ER70710-1160-03Listed by the FDA as Mirabegron50 mgtablet, extended releaseZydus Pharmaceuticals (USA) Inc. | 7,613.00 (Schedule G, line 182, page 11 of the filing PDF) | 30 |
| 183 | Vascepa cap 1 g52937-0001-20Listed by the FDA as Vascepaicosapent ethyl1,000 mgcapsuleAmarin Pharma Inc. | 7,567.74 (Schedule G, line 183, page 11 of the filing PDF) | 19 |
| 184 | Orilissa tab 150 mg00074-0038-28Listed by the FDA as Orilissaelagolix150 mgtablet, film coatedAbbVie Inc. | 7,541.81 (Schedule G, line 184, page 11 of the filing PDF) | 13 |
| 185 | Spiriva RESP aer 2.5 mcg00597-0100-61Listed by the FDA as Spiriva Respimattiotropium bromide inhalation spray3.124 mcgspray, meteredBoehringer Ingelheim Pharmaceuticals, Inc. | 7,499.89 (Schedule G, line 185, page 11 of the filing PDF) | 190 |
| 186 | Xyosted inj 50/0.5 mL54436-0250-04Listed by the FDA as Xyostedtestosterone enanthate50 mg/0.5 mLinjectionAntares Pharma, Inc. | 7,436.54 (Schedule G, line 186, page 11 of the filing PDF) | 25 |
| 187 | Invega Trinz inj 546 mg50458-0608-01Listed by the FDA as Invega Trinzapaliperidone palmitate546 mg/1.75 mLinjection, suspension, extended releaseJanssen Pharmaceuticals, Inc | 7,387.90 (Schedule G, line 187, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 188 | Xyosted inj 100/0.554436-0200-04Listed by the FDA as Xyostedtestosterone enanthate100 mg/0.5 mLinjectionAntares Pharma, Inc. | 7,317.90 (Schedule G, line 188, page 11 of the filing PDF) | 24 |
| 189 | Xcopri 150 mg71699-0150-30Listed by the FDA as Xcopricenobamate150 mgtablet, film coatedSK Life Science, Inc. | 7,316.54 (Schedule G, line 189, page 11 of the filing PDF) | 10 |
| 190 | Qulipta tab 30 mg00074-7096-30Listed by the FDA as Quliptaatogepant30 mgtabletAbbVie Inc. | 7,312.24 (Schedule G, line 190, page 11 of the filing PDF) | 15 |
| 191 | Flutic/Salme aer 115-2166993-0087-96Listed by the FDA as Fluticasone Propionate and Salmeterol HFAfluticasone propionate and salmeterol xinafoate115 mcg; 21 mcgaerosol, meteredPrasco Laboratories | 7,311.27 (Schedule G, line 191, page 11 of the filing PDF) | 45 |
| 192 | Flutic/Vilan inh 200-2566993-0136-97Listed by the FDA as Fluticasone Furoate and Vilanterol200 mcg; 25 mcgpowderPrasco Laboratories | 6,721.70 (Schedule G, line 192, page 11 of the filing PDF) | 43 |
| 193 | Gilenya cap 0.5 mg00078-0607-15Listed by the FDA as Gilenyafingolimod hcl0.5 mgcapsuleNovartis Pharmaceuticals Corporation | 6,712.92 (Schedule G, line 193, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 194 | Aristada inj 882 mg/365757-0403-03Listed by the FDA as Aristadaaripiprazole lauroxil882 mg/3.2 mLinjection, suspension, extended releaseAlkermes, Inc. | 6,671.12 (Schedule G, line 194, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 195 | MPB Xtandi 40 mg tab 12000469-0625-99Listed by the FDA as Xtandienzalutamide40 mgtabletAstellas Pharma US, Inc. | 6,424.81 (Schedule G, line 195, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 196 | Rexulti tab 0.25 mg59148-0035-13Listed by the FDA as Rexultibrexpiprazole0.25 mgtabletOtsuka America Pharmaceutical, Inc. | 6,400.40 (Schedule G, line 196, page 11 of the filing PDF) | 8 |
| 197 | Bupren/Nalox SUB 8-2 mg62756-0970-83Listed by the FDA as Buprenorphine and Naloxone8 mg; 2 mgtabletSun Pharmaceutical Industries, Inc. | 6,304.33 (Schedule G, line 197, page 11 of the filing PDF) | 394 |
| 198 | NuvaRing MIS59212-0146-03Listed by the FDA as NuvaRingetonogestrel and ethinyl estradiol0.12 mg/day; 0.015 mg/dayinsert, extended releaseAdvanz Pharma (US) Corp. | 6,248.06 (Schedule G, line 198, page 11 of the filing PDF) | 13 |
| 199 | Adalimu-adaz inj 40/0.4 mL61314-0327-20Listed by the FDA as Adalimumabadalimumab-adaz40 mg/0.4 mLinjection, solutionSandoz Inc | 5,981.71 (Schedule G, line 199, page 11 of the filing PDF) | 13 |
| 200 | Voquezna tab 10 mg81520-0100-30Listed by the FDA as Voqueznavonoprazan fumarate13.36 mgtabletPhathom Pharmaceuticals Inc. | 5,980.99 (Schedule G, line 200, page 11 of the filing PDF) | 16 |
| 201 | Cetirizine sol 1 mg/mL00121-0874-16Listed by the FDA as Cetirizine Hydrochloride1 mg/mLsolutionPAI Holdings, LLC dba PAI Pharma | 5,964.62 (Schedule G, line 201, page 11 of the filing PDF) | 504 |
| 202 | Ventolin HFA aer00173-0682-20Listed by the FDA as Ventolin HFAalbuterol sulfate90 mcgaerosol, meteredGlaxoSmithKline LLC | 5,959.08 (Schedule G, line 202, page 11 of the filing PDF) | 360 |
| 203 | Flutic/Salme aer 230-2166993-0088-96Listed by the FDA as Fluticasone Propionate and Salmeterol HFAfluticasone propionate and salmeterol xinafoate230 mcg; 21 mcgaerosol, meteredPrasco Laboratories | 5,955.03 (Schedule G, line 203, page 11 of the filing PDF) | 28 |
| 204 | Complera tab61958-1101-01Listed by the FDA as Compleraemtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate200 mg; 25 mg; 300 mgtablet, film coatedGilead Sciences, Inc. | 5,888.26 (Schedule G, line 204, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 205 | Spinosad sus 0.9%52246-0570-04Listed by the FDA as Spinosad9 mg/mLsuspensionParaPRO LLC | 5,789.97 (Schedule G, line 205, page 11 of the filing PDF) | 30 |
| 206 | Ingrezza 80 mg capsules70370-1080-01Listed by the FDA as Ingrezzavalbenazine80 mgcapsuleNeurocrine Biosciences, Inc. | 5,737.46 (Schedule G, line 206, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 207 | Ibuprofen tab 600 mg49483-0603-50Listed by the FDA as Ibuprofen600 mgtablet, film coatedTime Cap Laboratories, Inc | 5,682.50 (Schedule G, line 207, page 11 of the filing PDF) | 2,275 |
| 208 | Gabapentin tab 800 mg70010-0228-05Listed by the FDA as Gabapentin800 mgtablet, film coatedGranules Pharmaceuticals Inc. | 5,656.05 (Schedule G, line 208, page 11 of the filing PDF) | 1,162 |
| 209 | Veozah tab 45 mg00469-2660-30Listed by the FDA as Veozahfezolinetant45 mgtablet, film coatedAstellas Pharma US, Inc. | 5,619.97 (Schedule G, line 209, page 11 of the filing PDF) | 13 |
| 210 | Bupren/Nalox MIS 4-1 mg47781-0356-03Listed by the FDA as Buprenorphine and Naloxone Sublingual Film4 mg; 1 mgfilmAlvogen Inc. | 5,596.15 (Schedule G, line 210, page 11 of the filing PDF) | 113 |
| 211 | Liraglutide inj 18 mg/3 mL00480-3667-22Listed by the FDA as Liraglutide6 mg/mLinjectionTeva Pharmaceuticals USA, Inc. | 5,591.87 (Schedule G, line 211, page 11 of the filing PDF) | 16 |
| 212 | Estrad Val inj 40 mg/mL70700-0275-22Listed by the FDA as Estradiol valerate40 mg/mLinjectionXiromed, LLC | 5,562.88 (Schedule G, line 212, page 11 of the filing PDF) | 47 |
| 213 | Valtoco 15 mg NAS SP(10x7.5 mg)5 dose72252-0515-10Listed by the FDA as Valtocodiazepam7.5 mg/0.1 mLsprayNeurelis, Inc | 5,526.07 (Schedule G, line 213, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 214 | Insulin ASPA inj Flexpen73070-0103-15Listed by the FDA as Insulin Aspart100 IU/mLinjection, solutionNovo Nordisk Pharma, Inc. | 5,448.28 (Schedule G, line 214, page 11 of the filing PDF) | 82 |
| 215 | Flutic/Salme aer 45-21 mcg66993-0086-96Listed by the FDA as Fluticasone Propionate and Salmeterol HFAfluticasone propionate and salmeterol xinafoate45 mcg; 21 mcgaerosol, meteredPrasco Laboratories | 5,446.85 (Schedule G, line 215, page 11 of the filing PDF) | 42 |
| 216 | Trintellix tab 10 mg64764-0730-30Listed by the FDA as Trintellixvortioxetine10 mgtablet, film coatedTakeda Pharmaceuticals America, Inc. | 5,417.93 (Schedule G, line 216, page 11 of the filing PDF) | 79 |
| 217 | Caplyta cap 10.5 mg72060-0110-40Listed by the FDA as Caplytalumateperone10.5 mgcapsuleIntra-Cellular Therapies, Inc | 5,412.48 (Schedule G, line 217, page 11 of the filing PDF) | 6 |
| 218 | Oracea cap 40 mg00299-3822-30Listed by the FDA as Oraceadoxycycline40 mgcapsuleGalderma Laboratories, L.P. | 5,405.19 (Schedule G, line 218, page 11 of the filing PDF) | 8 |
| 219 | Estrad Val inj 20 mg/mL00143-9290-01Listed by the FDA as Estradiol Valerate20 mg/mLinjectionHikma Pharmaceuticals USA Inc. | 5,384.34 (Schedule G, line 219, page 12 of the filing PDF) | 88 |
| 220 | Estrad Val inj 40 mg/mL00143-9291-01Listed by the FDA as Estradiol Valerate40 mg/mLinjectionHikma Pharmaceuticals USA Inc. | 5,368.75 (Schedule G, line 220, page 12 of the filing PDF) | 57 |
| 221 | Belbuca MIS 750 mcg59385-0026-60Listed by the FDA as Belbucabuprenorphine hydrochloride750 mcgfilm, solubleBioDelivery Sciences International Inc | 5,342.58 (Schedule G, line 221, page 12 of the filing PDF) | 17 |
| 222 | Yuvafem tab 10 mcg65162-0226-21Listed by the FDA as Yuvafemestradiol10 mcgtabletAmneal Pharmaceuticals LLC | 5,311.12 (Schedule G, line 222, page 12 of the filing PDF) | 133 |
| 223 | Ingrezza cap 40 mg70370-2040-01Listed by the FDA as Ingrezzavalbenazine40 mgcapsuleNeurocrine Biosciences, Inc. | 5,263.04 (Schedule G, line 223, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 224 | Praluent inj 75 mg/mL61755-0020-02Listed by the FDA as Praluentalirocumab75 mg/mLinjection, solutionRegeneron Pharmaceuticals, Inc. | 5,238.92 (Schedule G, line 224, page 12 of the filing PDF) | 22 |
| 225 | Steglatro tab 5 mg00006-5363-03Listed by the FDA as Steglatroertugliflozin5 mgtablet, film coatedMerck Sharp & Dohme LLC | 5,196.48 (Schedule G, line 225, page 12 of the filing PDF) | 13 |
| 226 | Naloxone HCl spr 4 mg00480-3478-68Listed by the FDA as Naloxone Hydrochloride4 mg/0.1 mLspray, meteredTeva Pharmaceuticals, Inc. | 5,190.30 (Schedule G, line 226, page 12 of the filing PDF) | 174 |
| 227 | Nucala inj 100 mg/mL00173-0892-01Listed by the FDA as Nucalamepolizumab100 mg/mLinjection, solutionGlaxoSmithKline LLC | 5,177.42 (Schedule G, line 227, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 228 | Zubsolv SUB 2.9-0.7154123-0929-30Listed by the FDA as Zubsolvbuprenorphine hydrochloride and naloxone hydrochloride2.9 mg; 0.71 mgtablet, orally disintegratingOrexo US, Inc. | 5,124.55 (Schedule G, line 228, page 12 of the filing PDF) | 19 |
| 229 | Breyna 160/4.5 mcg oral inh(120 inh)00378-7503-32Listed by the FDA as Breynabudesonide and formoterol fumarate160 mcg; 4.5 mcgaerosol, meteredMylan Pharmaceuticals Inc. | 5,053.50 (Schedule G, line 229, page 12 of the filing PDF) | 14 |
| 230 | Depo Provera 150 mg66993-0370-25Listed by the FDA as Medroxyprogesterone Acetate150 mg/mLinjection, suspensionPrasco Laboratories | 165,078.48 (Schedule G, line 230, page 12 of the filing PDF) | 1,358 |
| 231 | Inj, cabote rilpivir 2 mg 3 mg49702-0240-15Listed by the FDA as Cabenuvacabotegravir and rilpivirinekitViiV Healthcare Company | 25,258.75 (Schedule G, line 231, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 232 | injection, Cabotegravir 1 mg49702-0264-23Listed by the FDA as ApretudecabotegravirkitViiV Healthcare Company | 9,004.95 (Schedule G, line 232, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 233 | IUD supplied - Kyleena50419-0424-01Listed by the FDA as Kyleenalevonorgestrel19.5 mgintrauterine deviceBayer HealthCare Pharmaceuticals Inc. | 10,650.60 (Schedule G, line 233, page 12 of the filing PDF) | 15 |
| 234 | IUD supplied - Mirena50419-0423-01Listed by the FDA as Mirenalevonorgestrel52 mgintrauterine deviceBayer HealthCare Pharmaceuticals Inc. | 67,403.64 (Schedule G, line 234, page 12 of the filing PDF) | 188 |
| 235 | IUD supplied - ParaGard59365-5129-01Listed by the FDA as ParaGard T 380Acopper313.4 mgintrauterine deviceCooperSurgical, Inc. | 13,222.88 (Schedule G, line 235, page 12 of the filing PDF) | 44 |
| 236 | IUD supplied - Skyla50419-0422-01Listed by the FDA as Skylalevonorgestrel13.5 mgintrauterine deviceBayer HealthCare Pharmaceuticals Inc. | 6,068.28 (Schedule G, line 236, page 12 of the filing PDF) | 6 |
| 237 | Rho Immune Globuilin (RH00562-7805-05Listed by the FDA as RhoGAM Ultra-Filtered PLUShuman Rho(D) immune globulin300 mcginjection, solutionKedrion Biopharma Inc | 10,454.07 (Schedule G, line 237, page 12 of the filing PDF) | 33 |
| 238 | Triamcinolone Acetonide 10 mg70121-1049-05Listed by the FDA as Triamcinolone Acetonide40 mg/mLinjection, suspensionAmneal Pharmaceuticals LLC | 6,929.60 (Schedule G, line 238, page 12 of the filing PDF) | 122 |
No row matches. | |||
| Total Prescription Drugs individually under $5,000 | 1,082,854.53 (Schedule G, row for amounts under $5,000, page 12 of the filing PDF) | 224,540 (Schedule G, claims on the row for amounts under $5,000, page 12 of the filing PDF) | |
| Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for ReimbursementThe list of drugs is based on the claims dispensed in the CY 2025, not on all drugs purchased in the CY 2025. | 14,485,262.62 (Schedule G, printed total, page 12 of the filing PDF) | 284,797 (Schedule G, printed claims total, page 12 of the filing PDF) | |
The rows at the foot of the table are always shown. The sum above does not include them.
What “fewer than 6” means. A count of 1 to 5 is not shown on this site or in its data files. Methods, section 9, says how.
Amounts and counts are the filer’s own, in US dollars. They are written here with commas between thousands, and an amount filed with one decimal place is written with two. No value is changed: the filing and the download keep each figure as typed.
Drug names are the filer’s own words. Filers type them in many ways, so this page writes them one way: capitals, spaces, unit names such as mg and mL, a zero before a decimal point, and commas in long numbers. No word is changed, spelled out or left out, and shorthand stays as the filer typed it. The filing and the download keep each name as typed, and a search here reads both.
“Listed by the FDA as” is not part of the filing. It is the name, ingredient, strength, form and labeler that the U.S. Food and Drug Administration’s National Drug Code Directory lists for the row’s code, as downloaded on 11 November 2026. 237 of the 238 rows have one. A row has none when its code is not filed as one 11-digit code or the directory has never listed it. Where the directory has since dropped a code, the name is kept as it was last listed, and the line says so. The directory’s capitals, strengths and unit names are written one way on this page. How a code is matched
Source
- Filing PDF
- Open Schedule G on the State of Rhode Island's website
- SHA-256
- b72c552b58da700253e7edcfde2ff426c14a8bdce4ff9110926c3d87dbb7106d
- Retrieved
- 11 November 2026
- Pages used
- 8 to 12 of 14